OM:ELOS B

Stock Analysis Report

Executive Summary

Elos Medtech AB (publ) develops and manufactures medical devices and components for the medtech industry.

Snowflake

Fundamentals

Good value with reasonable growth potential.

Share Price & News

How has Elos Medtech's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

ELOS B

5.5%

SE Medical Equipment

2.1%

SE Market


1 Year Return

64.5%

ELOS B

33.9%

SE Medical Equipment

12.1%

SE Market

Return vs Industry: ELOS B exceeded the Swedish Medical Equipment industry which returned 33.9% over the past year.

Return vs Market: ELOS B exceeded the Swedish Market which returned 12.1% over the past year.


Shareholder returns

ELOS BIndustryMarket
7 Day0%5.5%2.1%
30 Day0%1.8%1.6%
90 Day-3.8%2.6%3.8%
1 Year66.3%64.5%35.4%33.9%16.8%12.1%
3 Year7.2%-5.0%54.9%36.6%32.3%12.4%
5 Year55.2%32.5%72.9%44.6%62.9%28.4%

Price Volatility Vs. Market

How volatile is Elos Medtech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Elos Medtech undervalued compared to its fair value and its price relative to the market?

30.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: ELOS B (SEK100) is trading below our estimate of fair value (SEK144.79)

Significantly Undervalued: ELOS B is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: ELOS B is good value based on its PE Ratio (25x) compared to the Medical Equipment industry average (44x).

PE vs Market: ELOS B is poor value based on its PE Ratio (25x) compared to the Swedish market (16.9x).


Price to Earnings Growth Ratio

Low PEG Ratio: ELOS B is good value based on its PEG Ratio (1x)


Price to Book Ratio

PB vs Industry: ELOS B is good value based on its PB Ratio (1.5x) compared to the SE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is Elos Medtech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

25.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ELOS B's forecast earnings growth (25.2% per year) is above the savings rate (0.4%).

Earnings vs Market: ELOS B's earnings (25.2% per year) are forecast to grow faster than the Swedish market (9.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ELOS B's revenue (8.6% per year) is forecast to grow faster than the Swedish market (4.5% per year).

High Growth Revenue: ELOS B's revenue (8.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: ELOS B's Return on Equity is forecast to be low in 3 years time (9.4%).


Next Steps

Past Performance

How has Elos Medtech performed over the past 5 years?

4.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ELOS B's earnings have grown by 4.6% per year over the past 5 years.

Accelerating Growth: ELOS B's earnings growth over the past year (53.9%) exceeds its 5-year average (4.6% per year).

Earnings vs Industry: ELOS B earnings growth over the past year (53.9%) exceeded the Medical Equipment industry 17.3%.


Return on Equity

High ROE: ELOS B's Return on Equity (6%) is considered low.


Return on Assets

ROA vs Industry: ELOS B's Return on Assets is below or equal to the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: ELOS B has improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Elos Medtech's financial position?


Financial Position Analysis

Short Term Liabilities: ELOS B's short term assets (SEK315.7M) exceeds its short term liabilities (SEK162.4M)

Long Term Liabilities: ELOS B's short term assets (315.7M) do not cover its long term liabilities (339.8M)


Debt to Equity History and Analysis

Debt Level: ELOS B's debt to equity ratio (55.5%) is considered high

Reducing Debt: Insufficient data to determine if ELOS B's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: ELOS B's debt is well covered by operating cash flow (32%).

Interest Coverage: ELOS B's interest payments on its debt are well covered by EBIT (5x coverage).


Balance Sheet

Inventory Level: ELOS B has a high level of physical assets or inventory.

Debt Coverage by Assets: ELOS B's debt is covered by short term assets (assets are 1.064660x debt).


Next Steps

Dividend

What is Elos Medtech's current dividend yield, its reliability and sustainability?

1.00%

Current Dividend Yield


Dividend Yield vs Market

company1.0%marketbottom25%1.8%markettop25%4.6%industryaverage1.1%forecastin3Years1.2%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: ELOS B's dividend (1%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (1.81%).

High Dividend: ELOS B's dividend (1%) is low compared to the top 25% of dividend payers in the Swedish market (4.65%).

Stable Dividend: ELOS B is not paying a notable dividend for the Swedish market, therefore no need to check if payments are stable.

Growing Dividend: ELOS B is not paying a notable dividend for the Swedish market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: ELOS B is not paying a notable dividend for the Swedish market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ELOS B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of Elos Medtech's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Jan Wahlström (52yo)

3.3yrs

Tenure

0

Mr. Jan Wahlström has been the Chief Executive Officer and President of Elos Medtech AB since July 1, 2016. Mr. Wahlström joined Elos Medtech from his role as President of Larodan AB. Mr. Wahlström served  ...


Management Age and Tenure

3.3yrs

Average Tenure

49.5yo

Average Age

Experienced Management: ELOS B's management team is considered experienced (3.3 years average tenure).


Board Age and Tenure

2.6yrs

Average Tenure

61.5yo

Average Age

Experienced Board: ELOS B's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buykr96,76719 Jul 19
Mathias Andersson
EntityIndividual
Role
Unit CEO
Chief Executive Officer of Elos Medtech Microplast AB
Shares1,000
Max Pricekr101.50
Buykr87,00006 May 19
Jan Wahlström
EntityIndividual
Role
Chief Executive Officer
President & CEO
Shares1,000
Max Pricekr87.00

Ownership Breakdown


Management Team

  • Jan Wahlström (52yo)

    President & CEO

    • Tenure: 3.3yrs
  • Søren Olesen (58yo)

    CEO of Elos Medtech Pinol A/S & Business Unit Director of Dental

    • Tenure: 0yrs
  • Sören Larsson (54yo)

    President of Forshemgruppen AB

    • Tenure: 16.8yrs
  • Jodie Gilmore (48yo)

    CEO of Elos Medtech Onyx & Business Unit Director of Orthopedics

    • Tenure: 0yrs
  • Mathias Andersson (48yo)

    Chief Executive Officer of Elos Medtech Microplast AB

    • Tenure: 0yrs
  • Malin Gustavsson (47yo)

    Marketing Director

    • Tenure: 0yrs
  • Conny Jakobsson (50yo)

    Chief Executive Officer of Elos Medtech Tianjin Co. Ltd

    • Tenure: 0yrs
  • Sam Svännel (58yo)

    Chief Executive Officer of Elos Medtech Timmersdala AB

    • Tenure: 0yrs
  • Ewa Linsäter (49yo)

    Chief Financial Officer

    • Tenure: 0.3yrs
  • Anders Björklund (44yo)

    QA/RA Quality Director

    • Tenure: 0yrs

Board Members

  • Yvonne Mårtensson (66yo)

    Chairman

    • Tenure: 2.8yrs
    • Compensation: kr400.00k
  • Jon Risfelt (58yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: kr225.00k
  • Jeppe Magnusson (67yo)

    Director

    • Tenure: 7.8yrs
    • Compensation: kr175.00k
  • Anders Birgersson (61yo)

    Director

    • Tenure: 3.5yrs
    • Compensation: kr175.00k
  • Claes Hansson (62yo)

    Director

    • Tenure: 0.8yrs
  • Hanna Wilkman (52yo)

    Director

    • Tenure: 0.8yrs

Company Information

Elos Medtech AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Elos Medtech AB (publ)
  • Ticker: ELOS B
  • Exchange: OM
  • Founded: 1923
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr806.800m
  • Shares outstanding: 8.07m
  • Website: https://www.elosmedtech.com

Number of Employees


Location

  • Elos Medtech AB (publ)
  • Torsgatan 5B
  • Gothenburg
  • Västra Götaland County
  • 411 04
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ELOS BOM (OMX Nordic Exchange Stockholm)YesSeries B SharesSESEKMay 1993
ELOSBSBATS-CHIXE (BATS 'Chi-X Europe')YesSeries B SharesGBSEKMay 1993

Biography

Elos Medtech AB (publ) develops and manufactures medical devices and components for the medtech industry. The company operates in three segments: Orthopedics, Dental, and Life Science. Its products include ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 20:44
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.